AnalystsThomas ShraderThomas Shrader's Stock Forecasts
AnalystsThomas Shrader
Analyst Ranking
Bottom 7%
#4107 out of 4414 analysts
Average Return
-26.03%
Win Rate
20%7 out of 35
Risk vs Reward
Poor
Good
Thomas Shrader's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Inmune Bio IncINMB | +117.73% | $10.38 | $22.60 | 2020-09-01 - 2021-08-30 | Strong Buy |
Biohaven LtdBHVN | +86.62% | $16.74 | $31.24 | 2022-12-02 - 2023-11-28 | Strong Buy |
Geron CorpGERN | +54.29% | $1.05 | $1.62 | 2020-04-03 - 2021-04-01 | Strong Buy |
Inmune Bio IncINMB | +38.50% | $5.48 | $7.59 | 2022-05-24 - 2023-05-23 | Strong Buy |
Annexon IncANNX | +22.38% | $2.10 | $2.57 | 2023-05-25 - 2023-11-28 | Strong Buy |
Thomas Shrader Analyst Color
Get additional color on Thomas Shrader's coverage of popular stocks
Thomas Shrader's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Promis Neurosciences IncPMN | 1 | Strong Buy | $8.00 | +566.67% | Initiates Coverage On | 2 months ago |
Precision Biosciences IncDTIL | 1 | Strong Buy | $2.00 | +390.20% | Maintains | 4 months ago |
Annexon IncANNX | 2 | Strong Buy | $7.00 | +172.37% | Maintains | 6 months ago |
Coya Therapeutics IncCOYA | 1 | Strong Buy | $15.00 | +174.07% | Initiates Coverage On | 6 months ago |
Athira Pharma IncATHA | 2 | Strong Buy | $10.00 | +594.44% | Maintains | 8 months ago |
Bioatla IncBCAB | 3 | Strong Buy | $13.00 | +717.61% | Maintains | 8 months ago |
Verona Pharma PLCVRNA | 3 | Strong Buy | $31.00 | +130.65% | Maintains | 8 months ago |
Alector IncALEC | 1 | Strong Buy | $16.00 | +210.08% | Maintains | 9 months ago |
Biohaven LtdBHVN | 1 | Strong Buy | $24.00 | -23.18% | Initiates Coverage On | a year ago |
Vaxcyte IncPCVX | 1 | Strong Buy | $69.00 | N/A | Initiates Coverage On | a year ago |
Gain Therapeutics IncGANX | 2 | Strong Buy | $10.00 | N/A | Maintains | a year ago |
Sqz Biotechnologies CoSQZB | 2 | Strong Buy | $15.00 | N/A | Maintains | a year ago |
Acumen Pharmaceuticals IncABOS | 2 | Strong Buy | $22.00 | N/A | Maintains | a year ago |
Inmune Bio IncINMB | 2 | Strong Buy | $14.00 | N/A | Maintains | 2 years ago |
Sigilon Therapeutics IncSGTX | 1 | Strong Buy | $182.00 | N/A | Initiates Coverage On | 2 years ago |
Pliant Therapeutics IncPLRX | 1 | Strong Buy | $51.00 | N/A | Initiates Coverage On | 3 years ago |
Celularity IncCELU | 1 | Strong Buy | $16.00 | N/A | Initiates Coverage On | 3 years ago |
Oncosec Medical IncONCSQ | 1 | Strong Buy | $220.00 | N/A | Initiates Coverage On | 3 years ago |
Nuvation Bio IncNUVB | 1 | Strong Buy | $16.00 | N/A | Initiates Coverage On | 3 years ago |
Voyager Therapeutics IncVYGR | 1 | Hold | N/A | N/A | Downgrades | 3 years ago |
Eidos Therapeutics IncEIDX | 1 | Hold | N/A | N/A | Downgrades | 3 years ago |
Denali Therapeutics IncDNLI | 1 | Hold | N/A | N/A | Downgrades | 3 years ago |
89bio IncETNB | 1 | Strong Buy | $58.00 | N/A | Maintains | 3 years ago |
Checkmate Pharmaceuticals IncCMPI | 1 | Strong Buy | $29.00 | N/A | Initiates Coverage On | 3 years ago |
Geron CorpGERN | 1 | Strong Buy | $3.00 | N/A | Maintains | 4 years ago |
Acorda Therapeutics IncACOR | 1 | Hold | $840.00 | N/A | Maintains | 4 years ago |
Biogen IncBIIB | 3 | Hold | $346.00 | N/A | Downgrades | 5 years ago |
Momenta Pharmaceuticals IncMNTA | 2 | Strong Buy | N/A | N/A | Upgrades | 6 years ago |
Kite Pharma IncKITE | 1 | Hold | N/A | N/A | Downgrades | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.